Forty years ago, one of Dr. Stephen Hauser’s first patients was a young Harvard Law School graduate and White House aide with a case of multiple sclerosis that raced like a brush fire through her brain. She quickly lost her ability to speak, swallow, and breathe. She got married in a wheelchair in her hospital room, tethered to breathing and feeding tubes and dressed in her wedding gown.

“We had nothing to treat her with,” recalled Hauser, now director of the Weill Institute for Neurosciences at the University of California, San Francisco. It was such a searing moment for the young doctor, then at the beginning of his neurology training, that he decided to dedicate his career to MS research.

Unlock this article by subscribing to STAT Plus. To get you started, enjoy 50% off your first 3 months!


What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Leave a Comment

Please enter your name.
Please enter a comment.

  • Were SPMS patients studied at any point during ocrelizumab’s protracted development?
    It has been apparent to some of us for many years that different demyelinating diseases, historically lumped under the MS label, are responsible for the wide variations in form, course, treatment response and outcome.

  • I have primary progressive ms it has effected my legs and vision would it help me for my vision can i recover my lost vision please reply me
    Thank u

  • I have relapsing-remitting MS diagnosed in 2000. I’m 68 years old and just recently seeing a change in my left leg and how it functions. Slowly changes have occurred, over my 17 years of knowledge of this disease but it is embarrasing now that I need to drag along my left foot when walking. Wondering if this new drug might help or stop this from getting worse.???


  • I am so encouraged. I hv had
    MS 30 yrs diagnosed but 4 yrs
    before having symptoms. Went
    To new dr. at Vanderbilt on wed 3-29-17 told I would be good candidate for new drug
    for progressive MS and it was
    approved Thur. 3-30-17. It’s been a long battle and slow
    decline. The only exercise I
    get is the water which I hv
    done for 29 yrs. but is getting
    much harder to get there. I
    feel so blessed after many yrs.
    of prayer there is something
    that might help! May God Bless all of u.

  • Thank you for providing a very comprehensive article about this new drug but also the history, expected cost and how the B cell discovery could change ms research. As someone with PPMS, I’ve watched this drug and the trials closely. You provide one of the most succinct articles that I’ve read on the drug and future potential of this discovery. Thank you.

  • When will the study be done on Primary Progressive MS I very interested my friend send me this article I was missed diadosed they thought I had Relapsing but no

  • This is Rituximab rebranded, for the sake of keeping the patent active. Rituximab is used as part of the treatment protocol for some of the HSCT facilities that treat MS and other Autoimmune diseases. This is NOT NEW! They should be focusing on further research for HSCT for MS and other Autoimmune Diseases. Then the majority of people with MS etc. will be a lot better off.

  • I’m also very interested I’m a 48 year old woman with Rrms and also take Tecidera it’s getting more n more difficult each day I was Dx in 2011 after many years of testing. Please feel free to contact me I need some relief. Thank you

Your daily dose of news in health and medicine

Privacy Policy